Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Sep;104(1):45–48. doi: 10.1111/j.1476-5381.1991.tb12382.x

The antimigraine drugs ergotamine and dihydroergotamine are potent 5-HT1C receptor agonists in piglet choroid plexus.

A M Brown 1, T L Patch 1, A J Kaumann 1
PMCID: PMC1908284  PMID: 1786517

Abstract

1. Fozard & Gray (1989) proposed that migraine is mediated by stimulation of 5-HT1C receptors. We have examined the interaction of two effective anti-migraine agents, ergotamine and dihydroergotamine (DHE), with these receptors. Binding (inhibition of labelling by [3H]-mesulergine) and agonist activity (phosphoinositide hydrolysis) were measured in piglet choroid plexus, a tissue rich in 5-HT1C receptors. 2. The pKD for [3H]-mesulergine binding was 8.4. Ergotamine and DHE both inhibited [3H]-mesulergine binding with a pKD of 7.1. This was similar to the potency of m-chlorophenylpiperazine (m-CPP) (pKD 7.4) and rather less than that of 5-hydroxytryptamine (5-HT) (pKD 8.1). 3. Both ergotamine and DHE were full agonists (pEC50S 7.5 and 7.6 respectively) with potencies similar to that of 5-HT (pEC50 7.7) and greater than that of m-CPP (pEC50 7.1). Mesulergine 10(-7) M produced near-parallel rightward shifts of the concentration-response curves for all these agents of 1.8-2.2 log units, consistent with an action of the agonists at the same receptor. 4. There was no effect of prazosin, spiperone, mepyramine or atropine on the phosphoinositide hydrolysis induced by ergotamine, ruling out an action via alpha 1-adrenoceptors, 5-HT2, histamine H1, or muscarinic receptors. 5. It is concluded that, together with 5-HT, ergotamine and DHE are the most potent 5-HT1C agonists reported so far. These findings do not support the theory that 5-HT1C receptor activation causes migraine.

Full text

PDF
45

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ala-Hurula V., Myllylä V. V., Arvela P., Kärki N. T., Hokkanen E. Systemic availability of ergotamine tartrate after three successive doses and during continuous medication. Eur J Clin Pharmacol. 1979 Nov;16(5):355–360. doi: 10.1007/BF00605636. [DOI] [PubMed] [Google Scholar]
  2. Andersson P. G. Ergotamine headache. Headache. 1975 Jul;15(2):118–121. doi: 10.1111/j.1526-4610.1975.hed1502118.x. [DOI] [PubMed] [Google Scholar]
  3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  4. Brewerton T. D., Murphy D. L., Mueller E. A., Jimerson D. C. Induction of migrainelike headaches by the serotonin agonist m-chlorophenylpiperazine. Clin Pharmacol Ther. 1988 Jun;43(6):605–609. doi: 10.1038/clpt.1988.83. [DOI] [PubMed] [Google Scholar]
  5. Conn P. J., Sanders-Bush E. Agonist-induced phosphoinositide hydrolysis in choroid plexus. J Neurochem. 1986 Dec;47(6):1754–1760. doi: 10.1111/j.1471-4159.1986.tb13085.x. [DOI] [PubMed] [Google Scholar]
  6. Fozard J. R., Gray J. A. 5-HT1C receptor activation: a key step in the initiation of migraine? Trends Pharmacol Sci. 1989 Aug;10(8):307–309. doi: 10.1016/0165-6147(89)90061-8. [DOI] [PubMed] [Google Scholar]
  7. Hill S. J. Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev. 1990 Mar;42(1):45–83. [PubMed] [Google Scholar]
  8. Kaumann A. J. Piglet sinoatrial 5-HT receptors resemble human atrial 5-HT4-like receptors. Naunyn Schmiedebergs Arch Pharmacol. 1990 Nov;342(5):619–622. doi: 10.1007/BF00169055. [DOI] [PubMed] [Google Scholar]
  9. Megens A. A., Leysen J. E., Awouters F. H., Niemegeers C. J. Further validation of in vivo and in vitro pharmacological procedures for assessing the alpha 2/alpha 1-selectivity of test compounds: (1). Alpha-adrenoceptor antagonists. Eur J Pharmacol. 1986 Sep 23;129(1-2):49–55. doi: 10.1016/0014-2999(86)90335-3. [DOI] [PubMed] [Google Scholar]
  10. Pazos A., Hoyer D., Palacios J. M. The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol. 1984 Nov 27;106(3):539–546. doi: 10.1016/0014-2999(84)90057-8. [DOI] [PubMed] [Google Scholar]
  11. Pettibone D. J., Williams M. Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol. 1984 May 1;33(9):1531–1535. doi: 10.1016/0006-2952(84)90424-6. [DOI] [PubMed] [Google Scholar]
  12. Sanders-Bush E., Breeding M. Serotonin1c receptor reserve in choroid plexus masks receptor subsensitivity. J Pharmacol Exp Ther. 1990 Mar;252(3):984–988. [PubMed] [Google Scholar]
  13. Sanders S. W., Haering N., Mosberg H., Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol. 1986;30(3):331–334. doi: 10.1007/BF00541538. [DOI] [PubMed] [Google Scholar]
  14. Schoeffter P., Hoyer D. Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Naunyn Schmiedebergs Arch Pharmacol. 1989 Jun;339(6):675–683. doi: 10.1007/BF00168661. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES